There are plenty of good artificial intelligence (AI) stocks available to investors these days, and if you've got $1,000 to invest right now, you've likely thought about buying Micron Technology ...

AbbVie (NYSE: ABBV) was spun off from Abbott (NYSE: ABT) in 2013. That's an important fact to keep in mind when you look at AbbVie's Dividend King status. Technically, it hasn't increased its dividend ...

Space Exploration Technologies (NASDAQ: SPCX) took off like one of its Falcon 9 rockets in the immediate days following its initial public offering on June 12, 2026. That IPO was one for the record ...

Obviously, nobody owns a functioning crystal ball. So, take any predictions about someone else's future actions with a grain of salt. You can make educated guesses, however, based on a person's past ...

Over the last couple of years, Super Micro Computer (NASDAQ: SMCI) has dealt with some notable headwinds that have affected perceptions around the company.

Although Warren Buffett no longer heads Berkshire Hathaway, its stock trades and positions continue to attract plenty of attention.

A quantile analysis study identifies some green cryptocurrencies as better transmitters of volatility compared to green assets, challenging traditional assumptionsInvestors usually prefer ESG funds ...

Ethereum (CRYPTO: ETH) badly needs a new story, and its founder, Vitalik Buterin, is intent on creating exactly that. Buterin dropped a fresh draft of the network's long-term roadmap on July 4, ...

In recent trading, shares of Omega Healthcare Investors, Inc. (Symbol: OHI) have crossed above the average analyst 12-month target price of $32.62, changing hands for $32.66/share.

Jefferies analyst Blayne Curtis has raised the price target for Advanced Micro Devices (NASDAQ: AMD) to $640.00, suggesting a potential upside of 18.59% from its recent trading price. The ...

Calidi Biotherapeutics, Inc. (NYSE American: CLDI) is executing a 1-for-16 reverse stock split effective July 31, 2026. This corporate action aims to optimize market dynamics, enhance ...

AstraZeneca AZN announced that the European Commission (EC) has approved Etcamah (camizestrant) in combination with a CDK4/6 inhibitor for the first-line treatment of a certain type of breast cancer.